Systemic therapies for psoriatic disease and serious adverse events in older adults: a population-based cohort study

No abstract available.

Information

Citation

Drucker AM, Sutradhar R, Ling V, Eder L, Gomes T, Fralick M, Iskandar RJ, Li P, MacDougall S, Manolson M, Rochon PA, Tadrous M. J Invest Dermatol. 2025; S0022-202X(25)03528-6. Epub 2025 Nov 15.

View Source

Contributing ICES Scientists

Research Programs

Chronic Disease & Pharmacotherapy

Associated Topics

Associated Sites

ICES Central

Discover More

Journal Article

03/03/2026

Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab

Davies GA, Prica A, Ante Z, Liu N, Pond GR, Balitsky AK, Suleman A, Mozessohn L. Cancer. 2026; 132(5): e70327.

Journal Article

17/02/2026

Opioid agonist treatment dispensing trends between 2018 and 2022 across six Canadian provinces

Garg R, Hamzat B, Cheung G, Eurich D, Kaboré JL, De Léséleuc L, Liu Z, Missaoui H, Randall JR, Shearer D, Stock D, Yang J, Gomes T. Can J Physiol Pharmacol. 2026; Feb 17 [Epub ahead of print].

Journal Article

16/02/2026

A site selection process for enhanced programming in naturally occurring retirement communities and social housing: an equity- and data-driven methodology

Liu KJ, Hatzifilalithis S, Recknagel J, Bibi Ali Yar D, Pedulla J, Brunner K, Meschino L, Hahn-Goldberg S, Matai L, Boblitz A, Bruner K, Rochon PA, Savage RD. Can J Aging. 2026; 1-8. Epub 2026 Feb 16.

See All